Effect of carvedilol on the production of reactive oxygen species by HL-60 cells

Neuroendocrinology Letters

Volumn 29, Issue 5, 2008, Pages 779-783

  Lojek, Antonín ^a   Pečivová, Jana ^b   Mačičková, Tatiana ^b   Nosál', Radomír ^b   Papežíková, Ivana ^a   Číž, Milan ^a  

^a INSTITUTE OF BIOPHYSICS   (Czech Republic)

^b INSTITUTE OF EXPERIMENTAL PHARMACOLOGY AND TOXICOLOGY   (Slovakia)

Author keywords

Antioxidative properties; Carvedilol; Chemiluminescence; HL 60 cells; Reactive oxygen species

Indexed keywords

CARVEDILOL; PEROXY RADICAL; REACTIVE OXYGEN METABOLITE; TROLOX C;

ANTIOXIDANT ACTIVITY; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL STRAIN HL 60; CHEMOLUMINESCENCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN CELL; INCUBATION TIME; PHAGOCYTE; PROTEIN CONTENT; SCAVENGING SYSTEM;

EID: 57149141936     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Allen RC, Stjernholm RL, Steele RH (1972). Evidence for the generation of an electronic excitation state(s) in human polymorphonuclear leukocytes and its participation in bactericidal activity. Biochem Biophys Res Commun. 47:679-684.
2. Drabikova K, Jancinova V, Nosal R, Solik P, Murin J, Holomanova D (2006). On the antioxiclant activity of carvedilol in human polymorphonuclear leukocytes in vitro and ex vivo. Neuro Endocrinol Lett. 27 Suppl 2: 138-140.
3. Feuerstein GZ, Bril A, Ruffolo RR, Jr. (1997). Protective effects of carvedilol in the myocardium. Am J Cardiol. 80: 41L-45L.
4. Hrbac J, Gregor C, Machova M, Kralova J, Bystron T, Ciz M, Lojek A (2007). Nitric oxide sensor based on carbon fiber covered with nickel porphyrin layer deposited using optimized electropolymerization procedure. Bioelectrochemistry. 71: 46-53.
5. Cheng J, Kamiya K, Kodama I (2001). Carvedilol: molecular and cellular basis for its multifaceted therapeutic potential. Cardiovasc Drug Rev. 19: 152-171.
6. Jancinova V, Drabikova K, Nosal R, Holomanova D (2006). Extra-and intracellular formation of reactive oxygen species by human neutrophils in the presence of pheniramine, chlorpheniramine and brompheniramine. Neuro Endocrinol Lett. 27 Suppl 2: 141-143.
7. Lilius EM, Nuutila JT (2006). Particle-induced myeloperoxidase release in serially diluted whole blood quantifies the number and the phagocytic activity of blood neutrophils and opsonization capacity of plasma. Luminescence. 21: 148-158.
8. Lojek A, Kubala L, Cizova H, Ciz M (2002). A comparison of whole blood neutrophil chemiluminescence measured with cuvette and microtitre plate luminometers. Luminescence. 17: 1-4.
9. Nosal R, Jancinova V, Ciz M, Drabikova K, Lojek A, Fabryova V (2005). Inhibition of chemiluminescence by carvedilol in the cell-free system, whole human blood and blood cells. Scand J Clin Lab Invest. 65: 55-64.
10. Nosal R, Drabikova K, Jancinova V, Macickova T, Pecivova J, Holomanova D (2006). On the pharmacology and toxicology of neutrophils. Neuro Endocrinol Lett. 27 Suppl 2: 148-151.
11. Pecivova J, Macickova T, Lojek A, Gallova L, Ciz M, Nosal R, Holomanova D (2006). Effect of carvedilol on reactive oxygen species and enzymes linking innate and adaptive immunity. Neuro Endocrinol Lett. 27 Suppl 2: 160-163.
12. Soucek K, Pachernik J, Kubala L, Vondracek J, Hofmanova J, Kozubik A (2006). Transforming growth factor-beta1 inhibits all-trans retinoic acid-induced apoptosis. Leuk Res. 30: 607-623.
13. Varin F, Cubeddu LX, Powell JR (1986). Liquid chromatographic assay and disposition of carvedilol in healthy volunteers. J Pharm Sci. 75: 1195-1197.
14. Yang SP, Ho LJ, Cheng SM, Hsu YL, Tsao TP, Chang DM, Lai JH (2004). Carvedilol differentially regulates cytokine production from activated human peripheral blood mononuclear cells. Cardiovasc Drugs Ther. 18: 183-188.